Merck to acquire Imago BioSciences to expand blood disorder drugs portfolio

Pharma giant Merck will acquire Imago BioSciences, a Nasdaq-listed clinical stage biopharmaceutical company, for a price of $36 per share in cash, which translates to ... Read More